Clinical Trials | November 13, 2025
Philogen updates on Fibromun clinical study developments
FIBROSARC did not meet its primary PFS endpoint in the final analysi
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Enabling a new era in minimally invasive obesity treatment across Europe
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Subscribe To Our Newsletter & Stay Updated
